Pauls Stradins Clinical University Hospital
- Address
- lock Available on a paid plan
Pauls Stradins Clinical University Hospital - Advanced Clinical Research Center
Pauls Stradins Clinical University Hospital is a leading European medical research institution conducting comprehensive clinical trials across multiple therapeutic areas. The center demonstrates particular expertise in metabolic disorders, autoimmune diseases, and cardiovascular conditions, with a strong focus on innovative treatment approaches for complex chronic diseases.
- Gastroenterology: Ulcerative colitis and Crohn's disease research with novel biologics including risankizumab, mirikizumab, and ozanimod
- Metabolic and Endocrine Disorders: Type 2 diabetes management, diabetic retinopathy prevention, and hypercholesterolemia treatment optimization
- Neurology: Multiple sclerosis therapies with disease-modifying agents including ofatumumab, remibrutinib, and ocrelizumab
- Cardiovascular and Pulmonary Medicine: Heart failure with preserved ejection fraction, pulmonary arterial hypertension, and atrial fibrillation management
The hospital's research portfolio extends to specialized areas including oncology (non-small cell lung cancer, bladder cancer, prostate cancer), ophthalmology (age-related macular degeneration, diabetic macular edema), and hematology (immune thrombocytopenia, venous thromboembolism). With active participation in phase 2 and phase 3 trials, the center contributes to advancing evidence-based medicine through rigorous evaluation of novel therapeutics, biosimilars, and combination therapies. The institution's involvement in long-term extension studies demonstrates commitment to comprehensive safety monitoring and sustained patient care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 18 therapeutic areas and 15 of 206 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 201 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 37 by active trials.
- 1Eli Lilly & Co.3active
lock +36 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG9trials
lock +30 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pauls Stradins Clinical University Hospital
lock Showing 1 of 140 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 206 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 8 | Unknown | 2015-11-06 | 2025-04-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.